Evidence map›Paper›PMID 38986683›Full record

ArticleCancer medicine2024

Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy.

Yanan Sun, Jiahe Hu, Rongfang Wang, Xinlian Du, Xiaoling Zhang, Jiaoting E, Shaoyue Zheng, Yuxin Zhou, Ruishu Mou, Xuedong Li and 8 more

Abstract read
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yanan SunDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.ORCID 0009-0009-9341-5929
Jiahe HuDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.ORCID 0000-0001-8874-6090
Rongfang WangDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Xinlian DuDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Xiaoling ZhangDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.ORCID 0000-0002-4835-8648
Jiaoting EDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Shaoyue ZhengDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Yuxin ZhouDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Ruishu MouDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Xuedong LiDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Hanbo ZhangDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Ying XuDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Yuan LiaoHarbin Medical University, Harbin, Heilongjiang, China.
Wenjie JiangHarbin Medical University, Harbin, Heilongjiang, China.
Lijia LiuHarbin Medical University, Harbin, Heilongjiang, China.
Ruitao WangDepartment of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Jiuxin ZhuDepartment of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang, China.
Rui XieDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.ORCID 0000-0003-0357-6702

Funding

The Haiyan Foundation of the Harbin Medical University Cancer Hospital JJMS2021-03The Haiyan Foundation of the Harbin Medical University Cancer Hospital JJMS2021-22The Haiyan Foundation of the Harbin Medical University Cancer Hospital JJMS2021-23
6 · The paper itself

Abstract

objectiveThe purpose of the study is to construct meaningful nomogram models according to the independent prognostic factor for metastatic pancreatic cancer receiving chemotherapy.

methodsThis study is retrospective and consecutively included 143 patients from January 2013 to June 2021. The receiver operating characteristic (ROC) curve with the area under the curve (AUC) is utilized to determine the optimal cut-off value. The Kaplan-Meier survival analysis, univariate and multivariable Cox regression analysis are exploited to identify the correlation of inflammatory biomarkers and clinicopathological features with survival. R software are run to construct nomograms based on independent risk factors to visualize survival. Nomogram model is examined using calibration curve and decision curve analysis (DCA).

resultsThe best cut-off values of 966.71, 0.257, and 2.54 for the systemic immunological inflammation index (SII), monocyte-to-lymphocyte ratio (MLR), and neutrophil-to-lymphocyte ratio (NLR) were obtained by ROC analysis. Cox proportional-hazards model revealed that baseline SII, history of drinking and metastasis sites were independent prognostic indices for survival. We established prognostic nomograms for primary endpoints of this study. The nomograms' predictive potential and clinical efficacy have been evaluated by calibration curves and DCA.

conclusionWe constructed nomograms based on independent prognostic factors, these models have promising applications in clinical practice to assist clinicians in personalizing the management of patients.

Indexed as

InflammationNomogramsPancreatic NeoplasmsAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansKaplan-Meier EstimateLymphocytesMaleMiddle AgedMonocytesNeoplasm MetastasisNeutrophilsPrognosisProportional Hazards Modelschemotherapydrinkingliver metastasesmetastatic pancreatic cancernomogramsystemic immune–inflammation index

Identifiers

PMID38986683
PMCPMC11236459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.